Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2001
Industry: Medical Devices (Less-invasive interventional procedures)
Headquarters: Natick, Massachusetts
Boston Scientific is a global developer, manufacturer, and marketer of less-invasive medical devices used in interventional cardiology, electrophysiology, gastroenterology, neurovascular intervention, and other specialties. The company's strategy focuses on product diversity, innovation, and operational excellence to compete in a cost-conscious healthcare environment. In 2001, the company executed a significant growth strategy through internal development and strategic acquisitions.
Key Financial Metrics
Revenue: Net sales for 2001 were approximately $2.7 billion, a substantial increase from $1.8 million in 1979. International sales accounted for approximately 40% of total net sales.
Research and Development: The company expended approximately $275 million on R&D in 2001, representing approximately 10% of net sales.
Market Capitalization: As of March 15, 2002, the aggregate market value of common stock held by non-affiliates was approximately $7.5 billion. The closing stock price on March 15, 2002, was $24.06.
Employees: Approximately 14,400 employees as of December 31, 2001 (including 3,300 in international operations).
Allowances for Uncollectible Amounts: The balance for allowances for uncollectible amounts and sales returns was $62 million at year-end 2001, down from $67 million at year-end 2000.
Note: Specific figures for net profit, operating cash flow, gross margins, total debt, and liquidity ratios are incorporated by reference to the Consolidated Financial Statements (Exhibit 13.1) and are not explicitly detailed in the provided text.
Material Changes and Significant Events
- Acquisitions: Completed several strategic acquisitions in 2001 to expand technology portfolios, including:
- Cardiac Pathways Corporation: Added Chilli(R) Cooled Ablation Catheter and Realtime Position Management(R) System.
- Catheter Innovations, Inc.: Expanded venous access market presence.
- Embolic Protection, Inc.: Entered the U.S. embolic protection market with the FilterWire EX(TM) device.
- Interventional Technologies, Inc.: Added the Cutting Balloon(R) device.
- Quanam Medical Corporation: Broadened drug-delivery portfolio.
- RadioTherapeutics Corporation: Expanded oncology portfolio with radiofrequency ablation devices.
- Product Launches and Approvals: Received 22 FDA approvals/clearances and 25 CE Mark approvals. Launched the internally developed Express(TM) coronary stent in European and international markets in September 2001.
- Product Decline: Sales of the NIR(R) coronary stent (distributed from Medinol Ltd.) declined significantly throughout 2001, with Q4 sales down approximately 50% compared to Q1. NIR(R) sales represented 11% of worldwide sales in 2001, down from 15% in 2000.
- Operational Restructuring: Initiated a global operations plan to consolidate manufacturing, discontinue activities at three U.S. facilities, and displace approximately 1,800 manufacturing and support employees. The plan was expected to be substantially completed in the first half of 2002.
Outlook, Risks, and Contingencies
Guidance and Outlook:
- The company expects to increase R&D investment in 2002 to fund new product development and clinical trials, specifically for the TAXUS drug-eluting stent, carotid program, and Express coronary stent platform.
- Anticipates launching the TAXUS paclitaxel-eluting stent in international markets in 2002 and the U.S. in late 2003 pending regulatory approval.
- Expects the global market share of the NIR(R) coronary stent to continue to decline in 2002 due to eroding physician acceptance.
Legal Proceedings and Contingencies:
- Medinol Litigation: Ongoing disputes with Medinol Ltd. regarding the supply agreement for NIR(R) stents and allegations of trade secret misappropriation. Medinol sent a letter in February 2002 purporting to terminate the supply agreement, which the company intends to challenge.
- Patent Litigation: Active litigation against Johnson & Johnson/Cordis (regarding BX Velocity and Corinthian stents) and Medtronic (regarding balloon catheters and stent delivery systems). A jury previously awarded the company $8.3 million in damages regarding the Corinthian stent, though final judgment was pending as of the filing date.
- Product Liability: The company faces inherent risks of product liability claims, though management believes insurance coverage is adequate.
Risks:
- Regulatory: Delays or failures in obtaining FDA or international regulatory approvals for new products (e.g., TAXUS, Express).
- Competition: Intense competition in the coronary stent market, particularly from competitors introducing drug-eluting stents earlier than Boston Scientific.
- Reimbursement: Pressure from managed care and third-party payors to reduce prices and limit supplier choices.
- Supply Chain: Reliance on specific suppliers for components; potential disruption could adversely affect operations.
Investor Verification Checklist
- Verify the final financial impact of the 1,800 employee displacement and manufacturing consolidation plan on 2002 operating expenses.
- Monitor the status of the Medinol supply agreement dispute and its potential impact on NIR(R) stent revenue and litigation costs.
- Track the progress and results of the TAXUS IV clinical trial and subsequent FDA approval timeline for the drug-eluting stent.
- Review the Consolidated Financial Statements (Exhibit 13.1) for specific details on net income, cash flow, and debt levels not provided in the text summary.
- Assess the competitive landscape regarding drug-eluting stents from competitors like Guidant and Johnson & Johnson.